30-Second Takeaway
- GLP-1RAs provide the most durable glycemic control as second-line therapy for metformin-treated T2D with low–moderate CV risk.
- In T2D, lower systolic BP improves cardiovascular and renal outcomes without clear mortality penalty at usual outpatient levels.
- Sedentary time, 24-hour movement balance, and discharge pain are practical levers for post-hospital risk reduction.
Week ending January 24, 2026
Cardiometabolic control, movement behaviors, and simple clinical signals to reduce risk
GLP-1 receptor agonists most effectively prevent HbA1c failure when added to metformin in low–moderate CV risk T2D
This target trial emulation compared SGLT2 inhibitors, sulfonylureas, GLP-1 receptor agonists, and DPP-4 inhibitors added to metformin in GRADE-eligible adults with T2D. GLP-1RAs reduced risk of HbA1c ≥7.0% versus sulfonylureas (HR 0.73; 95% CI 0.68-0.78) and DPP-4 inhibitors (HR 0.65; 95% CI 0.60-0.70). SGLT2 inhibitors showed similar glycemic durability to DPP-4 inhibitors but were inferior to GLP-1RAs (HR 1.60; 95% CI 1.48-1.72) and sulfonylureas (HR 1.17; 95% CI 1.11-1.23). Findings support GLP-1RAs as the most effective second-line option for glycemic durability in metformin-treated T2D without recent cardiovascular events.
Lower blood pressure in T2D improves CV and renal outcomes without clear low-SBP mortality harm
This dose–response meta-analysis included 89 cohorts and 5.88 million people with type 2 diabetes to evaluate BP–outcome relationships. Systolic BP displayed J-shaped associations with mortality and cardiovascular events, but risk flattened rather than increased at lower pressures. After excluding cohorts with baseline CVD or cancer, lower systolic BP was associated with fewer cardiovascular events and no excess all-cause mortality. Higher BP showed linear or monotonic associations with renal events, eGFR decline, and albuminuria progression, supporting tighter BP control for renal protection.
Apple Watch screening substantially increases detection of new atrial fibrillation in older high-stroke-risk adults
This randomized trial enrolled 437 adults ≥65 years with elevated CHA2DS2-VASc scores to six months of Apple Watch monitoring or standard care. New-onset AF occurred in 9.6% of smartwatch users versus 2.3% with usual care, a 7.3 percentage point absolute increase (P=0.001). The hazard of detecting AF was 4.40 times higher with smartwatch screening (95% CI 1.66-11.66), including asymptomatic episodes detected only in the intervention arm. These results indicate smartwatch-based AF monitoring can meaningfully increase AF diagnosis among older adults at high stroke risk.
References
Numbered in order of appearance. Click any reference to view details.
Additional Reads
Optional additional studies from this edition.